Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2017

Open Access 01-12-2017 | Research article

Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines

Authors: Priya Bahri, Julianna Fogd, Daniel Morales, Xavier Kurz, on behalf of the ADVANCE consortium

Published in: BMC Medicine | Issue 1/2017

Login to get access

Abstract

Background

The benefit-risk balance of vaccines is regularly debated by the public, but the utility of media monitoring for regulatory bodies is unclear. A media monitoring study was conducted at the European Medicines Agency (EMA) concerning human papillomavirus (HPV) vaccines during a European Union (EU) referral procedure assessing the potential causality of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) reported to the authorities as suspected adverse reactions.

Methods

To evaluate the utility of media monitoring in real life, prospective real-time monitoring of worldwide online news was conducted from September to December 2015 with inductive content analysis, generating ‘derived questions’. The evaluation was performed through the validation of the predictive capacity of these questions against journalists’ queries, review of the EMA’s public statement and feedback from EU regulators.

Results

A total of 4230 news items were identified, containing personal stories, scientific and policy/process-related topics. Explicit and implicit concerns were identified, including those raised due to lack of knowledge or anticipated once more information would be published. Fifty derived questions were generated and categorised into 12 themes. The evaluation demonstrated that providing the media monitoring findings to assessors and communicators resulted in (1) confirming that public concerns regarding CRPS and POTS would be covered by the assessment; (2) meeting specific information needs proactively in the public statement; (3) predicting all queries from journalists; and (4) altering the tone of the public statement with respectful acknowledgement of the health status of patients with CRSP or POTS.

Conclusions

The study demonstrated the potential utility of media monitoring for regulatory bodies to support communication proactivity and preparedness, intended to support trusted safe and effective vaccine use. Derived questions seem to be a familiar and effective format for presenting media monitoring results in the scientific-regulatory environment. It is suggested that media monitoring could form part of regular surveillance for medicines of high public interest. Future work is recommended to develop efficient monitoring strategies for that purpose.
Appendix
Available only for authorised users
Literature
1.
Leach M, Fairhead J. Vaccine anxieties: global science, child health and society. London: Taylor & Francis Earthscan; 2007.
2.
3.
4.
Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf. 2010;33:1065–79.CrossRefPubMed
5.
Larson H, Brocard Paterson P, Erondu N. The globalization of risk and risk perception: why we need a new model of risk communication for vaccines. Drug Saf. 2012;35:1053–9.
6.
7.
Odone A, Chiesa V, Ciorba V, Cella P, Pasquarella C, Signorelli C. Influenza and immunization: a quantitative study of media coverage in the season of the ‘Fluad case’. Epidemiol Prev. 2015;39 Suppl 1:139–45.PubMed
8.
9.
Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine. 2010;28:2070–5.CrossRefPubMed
10.
Gerhardus A, Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. J Epidemiol Community Health. 2010;64:377–8.CrossRefPubMed
11.
Nghi NQ, Lamontagne DS, Bingham A, Rafiq M, le Mai TP, Lien NT, Khanh NC, Hong DT, Huyen DT, Tho NT, Hien NT. Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health. 2010;7:262–70.CrossRefPubMed
12.
Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. J Am Med Assoc. 2009;302:781–6.CrossRef
13.
Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M. Chapter 25: education, training, and communication for HPV vaccines. Vaccine. 2006;24 Suppl 3:S3 210–8.
14.
Tafuri S, Martinelli D, Vece MM, Quarto M, Germinario C, Prato R. Communication skills in HPV prevention: an audit among Italian healthcare workers. Vaccine. 2010;28:5609–13.CrossRefPubMed
15.
Friedman AL, Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav. 2007;34:471–85.CrossRefPubMed
16.
Bingham A, Drake JK, LaMontagne DS. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med. 2009;163:455–61.CrossRefPubMed
17.
Brown EC, Little P, Leydon GM. Communication challenges of HPV vaccination. Fam Pract. 2010;27:224–9.CrossRefPubMed
18.
Chow SN, Soon R, Park JS, Pancharoen C, Qiao YL, Basu P, Ngan HY. Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. Vaccine. 2010;28:3809–17.CrossRefPubMed
19.
20.
21.
Ritchie J, Lewis J, editors. Qualitative research practice: a guide for social science students and researchers. London: Sage; 2003.
22.
Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2007;62:107–15.CrossRef
23.
24.
25.
26.
Morgan MG, Fischhoff B, Bostrom A, Atman CJ. Risk communication: a mental model approach. Cambridge: Cambridge University Press; 2002.
27.
Kasperson RE, Renn O, Slovic P, Brown HS, Emel J, Goble R, Kasperson JX, Ratick S. The social amplification of risk: a conceptual framework. Risk Anal. 1988;8:177–87.CrossRef
28.
Renn O, Levine D. Credibility and trust in risk communication. In: Kasperson R, Stallen P, editors. Communicating risks to the public. Boston: Kluwer; 1991. p. 175–218.CrossRef
29.
30.
Cabut S. Etude rassurante sur les vaccins contre le cancer du col de l’utérus. Paris: Le Monde; 2015.
31.
Associated Press staff. GOP lawmakers ask schools to oppose HPV vaccine mandate. Washington DC: The Washington Times; 2015.
32.
CBC News staff. HPV vaccine not as effective as abstinence, B.C. bishop tells parents. Toronto: CBC News; 2015.
33.
Findalen J, Cuculiza M. Danmark dropper omstridt HPV-vaccine. Copenhagen: Metroxpress; 2015.
34.
Ritzau A. Flere piger end ventet har HPV-bivirkninger: så mange er ramt. Søgade: sn.dk; 2015.
35.
Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol Biomarkers Prev. 2015;24:1673–9. Epub October 22 2015.CrossRefPubMedPubMedCentral
36.
International Papillomavirus Society. The International Papillomavirus Society endorses human papillomavirus vaccines [press release]. New York: PR Newswire; 2015.
37.
Weber C, Andersen S. Firma bag HPV-vaccinen underdrev omfanget af alvorlig lidelse. Copenhagen: Metroxpress (original from Radio24syv); 2015.
38.
Lu PJ, Yankey D, Jeyarajah J, O’Halloran A, Elam-Evans LD, Smith PJ, Stokley S, Singleton JA, Dunne EF. HPV vaccination coverage of male adolescents in the United States. Pediatrics. 2015;136:839–49. Epub 26 October 2016.
39.
Canadian Press. HPV vaccine Gardasil review finds no evidence of new risks: Health Canada. Toronto: CBC News; 2015.
40.
ITV plc staff. Claims that cancer vaccine caused girl’s ill health. London: ITV online UK; 2015.
41.
Heaney T. We must stop HPV vaccine. Cork: The Irish Examiner; 2015.
42.
SaneVax. Irish government calls for investigations on Gardasil vaccine injuries. Austin: Health Impact News; 2015.
43.
Youle E. Mother tells of daughter’s debilitating illness as Ham&High investigates HPV vaccine safety. London: Ham&High; 2015.
44.
The Liberty Beacon staff. HPV vaccines proven to be ineffective, dangerous & even deadly. USA: The Liberty Beacon; 2015.
45.
Rail G, Molino L, Lippman L. Appel urgent à un moratoire sur la vaccination contre les VPH. Montreal: Le Devoir; 2015.
46.
Fu LY, Zook K, Spoehr-Labutta Z, Hu P, Joseph JG. Search engine ranking, quality, and content of web pages that are critical versus noncritical of human papillomavirus vaccine. J Adolesc H. 2016;58:33–9.CrossRef
47.
Holst C. HPV-piger risikerer opslidende tur i arbejdsprøvnings-karrusel. Copenhagen: Avisen.dk, Ekstra Bladet; 2015.
48.
49.
Herald Scotland staff. Schoolgirls should stop being given HPV vaccine until investigation into side effects, campaigner says. Glasgow: Herald Scotland; 2015.
50.
El Economista staff. Afectados por la vacuna del virus del papiloma humano piden a sanidad que haga un seguimiento de los casos detectados. Madrid, Barcelona: El Economista (SERVIMEDIA); 2015.
51.
The Irish Times staff. Mother fails to get order withdrawing cervical cancer vaccine. Dublin: The Irish Times; 2015.
52.
REGRET. REGRET.IE launches national register appeal for injured girls. R.E.G.R.E.T. (Reactions and Effects of Gardasil Resulting in Extreme Trauma) Support Group. Ireland: REGRET.ie; 2015.
53.
Birrell F, Hinks S. UK Association of HPV Vaccine Injured Daughters (AHVID). SaneVax, Inc (Safe, Affordable, Necessary & Effective Vaccines and Vaccination Practices); 2015
54.
Freyer FJ. Parents protest R.I. mandating HPV vaccine for teens. Boston: Boston Globe online; 2015.
55.
Fifield A. The science doesn’t support them, but Japanese anti-vaxxers are winning on HPV. Washington DC: The Washington Post; 2015.
56.
Carley MJ. Autism without fear: hold it - Donald Trump’s a moron on vaccines? No: Washington’s a moron on vaccines! USA: Huffington Post Online (blog); 2015.
57.
World Health Organization (WHO). Uganda launches human papillomavirus vaccine. Geneva: WHO; 2015.
58.
Kimani G. Tanzania: Gov’t urged to create a cervical cancer tree Tanzania. Cape Town, Dakar, Lagos, Monrovia, Nairobi, Washington DC: allafrica.com; 2015.
59.
Dwyer D. Boston Medical Center awarded grant to improve HPV vaccination rates through provider education. Boston: Boston.com; 2015.
60.
Panagiotou OA, Befano BL, Gonzalez P, Rodríguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, Wacholder S, on behalf of the Costa Rica HPV Vaccine Trial (CVT) Group. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. Br Med J. 2015;351:h4358.CrossRef
61.
Petráš M, Adámková V. Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: population-based crosssectional survey of Czech women aged 16 to 40 years. Vaccine. 2015;33:6264–7.
62.
Sundhedsstyrelsen (Danish health authority). Kraftigt fald i forekomsten af kondylomer blandt unge kvinder og mænd. Copenhagen: Sundhedsstyrelsen; 2015.
63.
Evans S. The government has been urged to consider changing its policies over HPV vaccinations to stop the spread of mouth cancer. UK: Dentistry.co.uk; 2015.
64.
Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among female adolescents in managed care plans: United States, 2013. Atlanta: CDC; 2015.
65.
Pharmaceutical Business Review (PBR) staff. FDA approves expanded age indication for Merck’s Gardasil 9 in males. London: PBR Regulatory Affairs; 2015.
66.
Secher M. Overlæge og DF: ny HPV-konklusion er forudsigelig og bekymrende. Odense: TV2 Denmark; 2015.
67.
Kenfelt M. HPV-lavinen. Copenhagen: Metroxpress Blog; 2015.
68.
Schreier D. Impfen: Verflechtungen mit der Industrie. Germany: Netzfrauen; 2015.
69.
Findalen J, Cuculiza M. Kræver HPV-vaccinen undersøgt af uafhængige. Copenhagen: Metroxpress; 2015.
70.
Chustecka Z. Chronic symptoms after HPV vaccination: Danes start study. New York: Medscape; 2015.
Metadata
Title
Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines
Authors
Priya Bahri
Julianna Fogd
Daniel Morales
Xavier Kurz
on behalf of the ADVANCE consortium
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2017
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-017-0850-4

Other articles of this Issue 1/2017

BMC Medicine 1/2017 Go to the issue

Research article

A 25-gene classifier predicts overall survival in resectable pancreatic cancer

Research article

Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study

Research article

Spatial model for risk prediction and sub-national prioritization to aid poliovirus eradication in Pakistan

Opinion

Ethics review in compassionate use

Commentary

Food for thought: why does the medical community struggle with research about nutritional therapy in the acute care setting?

Research article

A unique pattern of cortical connectivity characterizes patients with attention deficit disorders: a large electroencephalographic coherence study